Americans Think Marijuana And Psychedelics Are Much Safer Now Than They Did A Decade Ago, Federal Study Shows
From toxifillers.com with love
As the marijuana legalization movement has expanded—and psychedelics policy has increasingly entered the mainstream conversation—a new survey shows that Americans don’t view cannabis and LSD as harmful as they once did.
A new analysis of the National Survey of Drug Use and Health (NSDUH), conducted annually by the federal Substance Abuse and Mental Health Services Administration (SAMHSA), found broadly that “perceptions of harm associated with substance use have been steadily declining for most substances since 2015.”
That’s especially true of marijuana, the review from the consulting firm Carnevale Associates, LLC explains. While risk perception has declined across multiple substances over the past decade, it was down “considerably” for cannabis—though the survey revealed “slightly more variability from year to year.”
Medical Marijuana Use Linked To Improved Quality Of Life
Medical marijuana use is linked to improved quality of life for patients with neurological disorders, enhancing job performance, sleep, appetite, and energy.
“Medical cannabis has been used to relieve symptoms for various chronic diseases,” the authors noted, “yet it remains stigmatized.”
The study revealed that 58% of respondents found medical cannabis effective for their condition.
Among them, 96% reported symptom relief, and 88% noted improved professional performance.
Additionally, 79% experienced better sleep, 71% had improved appetite, and 68% reported increased energy and vitality.
These findings align with other recent research showing that cannabis can enhance general well-being.
Studies have shown significant improvements in quality of life for individuals with chronic pain and insomnia who use medical cannabis.
0 seconds of 1 minute, 10 secondsVolume 0%
“From 2015 to 2023, the NSDUH shows steady (i.e., regular, yearly) declines in perceptions of harm across ‘frequent’ and ‘less frequent’ use for cigarettes, heroin, LSD, and cocaine,” the firm, which was founded by a former top staffer in the White House Office of National Drug Control Policy, said. “Marijuana’s decline was the largest of any substance over the period (-30 percent for both types of use), though it showed very slight variability by year.”
Notably, perceptions of harm for the psychedelic LSD “experienced the largest decline over the period for more frequent use (-14 percent) and less frequent use (-20 percent),” it said. “For cigarettes, heroin, LSD, and cocaine, diminishing perceptions of harm were slightly more pronounced among youth and young adults.”
“The changing perceptions of harm associated with LSD illustrate the pattern,” the report continued. “For trying LSD once or twice, overall perception of harm decreased -20 percent. By age group, perception of harm declined by 19 percent among adults aged 26+, 23 percent among youth aged 12-17, and by 31 percent among young adults aged 18-25.”
For marijuana, risk perceptions for monthly and weekly use both decreased by 30 percent from 2015 to 2023.
“Perceptions of harm associated with substance use have been steadily softening for many years. This softening is apparent across most substances and age groups,” Carnevale Associates said. “Since perceived risk of harm is often considered a leading indicator of substance use trends, policymakers and practitioners should continue to monitor substance use trends closely.”
While it is the case that risk perception is often associated with usage trends, it should be noted that, for cannabis at least, that hasn’t always borne out in the data.
Despite prohibitionist warnings about lower perceptions of harm potentially leading more underage people to use marijuana, multiple national surveys have found that, even as that sense of concern about health impacts has declined, rates of cannabis use have been stable, or even declined, among teens—including in states that have enacted legalization.
To advocates, that isn’t an especially surprising finding, as supporters of legalization have long argued that establishing a regulatory framework for marijuana sales where there are safeguards in place (e.g. age restrictions and ID checks at licensed retailers) would mitigate youth access.
A study published in the journal Pediatric Reports in October revealed a “significant decrease” in youth marijuana use from 2011 to 2021—a period in which more than a dozen states legalized marijuana for adults—detailing lower rates of both lifetime and past-month use by high-school students nationwide.
In Washington State—the second state in the country to launch an adult-use marijuana market—data from a recent survey of adolescent and teenage students found that perceived ease of access to cannabis among underage students has generally dropped since the state enacted legalization for adults in 2012. That survey also showed overall declines in both lifetime and past-30-day marijuana use since legalization, with striking drops in recent years that held steady through 2023.
A separate 2018 survey, however, did suggest that fewer teens perceived occasional or frequent cannabis use to be harmful, even though underage use rates had not increased.
Data from CDC’s 2023 Youth Risk Behavior Survey, meanwhile, was released earlier this year. The updated numbers show a continued decline in the proportion of high-school students reporting past-month marijuana use over the past decade.
Another federal report published this summer concluded that cannabis consumption among minors—defined as people 12 to 20 years of age—fell slightly between 2022 and 2023.
Separately, a research letter published by the Journal of the American Medical Association (JAMA) in April said there’s no evidence that states’ adoption of laws to legalize and regulate marijuana for adults have led to an increase in youth use of cannabis.
Another JAMA-published study earlier that month that similarly found that neither legalization nor the opening of retail stores led to increases in youth cannabis use.
A separate study late last year also found that Canadian high-school students reported it was more difficult to access marijuana since the government legalized the drug nationwide in 2019. The prevalence of current cannabis use also fell during the study period, from 12.7 percent in 2018–19 to 7.5 percent in 2020–21, even as retail sales of marijuana expanded across the country.
In December, meanwhile, a U.S. health official said that teen marijuana use has not increased “even as state legalization has proliferated across the country.”
“There have been no substantial increases at all,” said Marsha Lopez, chief of the National Institute on Drug Abuse’s (NIDA) epidemiological research branch. “In fact, they have not reported an increase in perceived availability either, which is kind of interesting.”
Another earlier analysis from CDC found that rates of current and lifetime cannabis use among high school students have continued to drop amid the legalization movement.
A study of high school students in Massachusetts that was published last November found that youth in that state were no more likely to use marijuana after legalization, though more students perceived their parents as cannabis consumers after the policy change.
A separate NIDA-funded study published in the American Journal of Preventive Medicine in 2022 also found that state-level cannabis legalization was not associated with increased youth use. The study demonstrated that “youth who spent more of their adolescence under legalization were no more or less likely to have used cannabis at age 15 years than adolescents who spent little or no time under legalization.”
Yet another 2022 study from Michigan State University researchers, published in the journal PLOS One, found that “cannabis retail sales might be followed by the increased occurrence of cannabis onsets for older adults” in legal states, “but not for underage persons who cannot buy cannabis products in a retail outlet.”
The trends were observed despite adult use of marijuana and certain psychedelics reaching “historic highs” in 2022, according to separate data released last year.
Photo courtesy of Brian Shamblen.